Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of “Buy” by Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have received an average recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $5.50.

CNTX has been the subject of several research reports. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Thursday, May 8th. William Blair reiterated an “outperform” rating on shares of Context Therapeutics in a report on Tuesday, April 29th. Piper Sandler reiterated an “overweight” rating and set a $4.00 target price (down from $4.50) on shares of Context Therapeutics in a research report on Thursday, June 26th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st.

Context Therapeutics Stock Performance

Context Therapeutics stock opened at $0.66 on Thursday. Context Therapeutics has a 52 week low of $0.49 and a 52 week high of $2.75. The stock has a market capitalization of $58.77 million, a P/E ratio of -2.11 and a beta of 1.87. The stock has a fifty day moving average of $0.71 and a 200-day moving average of $0.82.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). On average, research analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current year.

Insider Activity at Context Therapeutics

In other news, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average price of $0.64 per share, with a total value of $25,606.40. Following the completion of the purchase, the chief financial officer directly owned 80,010 shares of the company’s stock, valued at approximately $51,206.40. This represents a 100.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Martin A. Lehr purchased 100,000 shares of the firm’s stock in a transaction on Monday, June 9th. The shares were acquired at an average price of $0.70 per share, with a total value of $70,000.00. Following the completion of the acquisition, the chief executive officer owned 920,190 shares in the company, valued at approximately $644,133. This trade represents a 12.19% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 160,010 shares of company stock valued at $107,206. Company insiders own 3.04% of the company’s stock.

Institutional Investors Weigh In On Context Therapeutics

Large investors have recently added to or reduced their stakes in the business. MPM Bioimpact LLC bought a new stake in shares of Context Therapeutics in the 4th quarter valued at $15,441,000. Blue Owl Capital Holdings LP increased its stake in Context Therapeutics by 17.5% in the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock valued at $6,676,000 after purchasing an additional 946,638 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Context Therapeutics by 115.9% during the fourth quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock valued at $4,204,000 after purchasing an additional 2,149,392 shares during the period. Allostery Investments LP acquired a new position in shares of Context Therapeutics during the fourth quarter valued at about $998,000. Finally, Geode Capital Management LLC boosted its position in shares of Context Therapeutics by 9.2% during the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock worth $661,000 after purchasing an additional 52,830 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.